Canada-based Clementia Pharmaceuticals has completed patient enrolment in its Phase II clinical trial of palovarotene, a retinoic acid receptor gamma agonist, to treat fibrodysplasia ossificans progressiva (FOP).

FOP is a rare disease that causes progressively disabling heterotopic bone formation (heterotopic ossification) in muscle and soft tissues.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase II trial is to evaluate the effect of palovarotene on new bone formations during and after a ‘flare-up’, an inflammatory event of varying severity and duration that often precedes heterotopic ossification.

The company noted the trial’s multiple clinical endpoints, including imaging endpoints for new bone formation, and clinical assessments of physical function and patient-reported outcomes.

"The data from this trial will be instrumental in designing the next steps in Clementia’s clinical programme for FOP."

Top-line data from the trial is expected to be reported by the end of this year.

Perelman School of Medicine Molecular Orthopaedic Medicine Division chief Dr Frederick Kaplan said: "The data from this trial will be instrumental in designing the next steps in Clementia’s clinical programme for FOP, as well as furthering our understanding of FOP and the impact that flare-ups have on the course of the disease."

Preclinical trials of palovarotene show that it blocked abnormal bone formation in animal models.

The company had licensed the treatment from Roche Pharmaceuticals, which previously evaluated it in more than 800 subjects.

Palovarotene also secured fast-track designation from the US Food and Drug Administration (FDA), as well as orphan designations to treat FOP from both the FDA and the European Medicines Agency (EMA).

Clementia founder and CEO Clarissa Desjardins said: "Completing enrolment in the Phase II trial represents another significant milestone in our clinical programme and moves us closer to our goal of potentially bringing a much-needed treatment to people with FOP.

"We are grateful to the study participants and their families, the FOP community, and the clinical trial site teams for their commitment to this effort."